Drugs / REIMMUGEN
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02920125 | Jan 2016 → Aug 2017 | cerebrovascular disorder, coronary artery disorder, ischemic disease, peripheral arterial disease +1 | Sujata Vaidya | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | REIMMUGEN | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02920125 ↗ |
| Modality | Protein / enzyme biologic | “Reimmugen (Cow Colostrum - IgG, GF) provides sustained Functional, symptomatic relief with clinical reports of regression of disease.” NCT02920125 ↗ |